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Background:  Inflammatory biomarkers appear to characterize residual cardiovascular (CV) risk on top of traditional risk factors. GlycA is 
a serum measurement of enzymatically glycosylated acute phase proteins. GlycA correlates with existing inflammatory biomarkers such 
as C-reactive protein and interleukin-6, but, importantly, has lower intra-individual variability over time. Thus, we hypothesized that GlycA 
would be associated with incident CV events and would improve on CV risk prediction beyond traditional risk factors.
methods:  GlycA levels were measured by LipoScience using nuclear magnetic resonance spectroscopy in 6,939 individuals in the 
CATHGEN biorepository. Association of GlycA with time to death or myocardial infarction was tested by Cox proportional hazards adjusting 
for age, sex, race, diabetes, hypertension, hyperlipidemia, smoking status, body-mass index, extent of coronary artery disease and ejection 
fraction. The incremental predictive value of GlycA for estimating CV risk was assessed by model fit statistics and by risk reclassification 
analysis after adding GlycA to the GRACE Risk Score.
results:  GlycA was strongly associated with incident CV events after adjustment for clinical risk factors [hazard ratio (95% confidence 
interval) 1.38 (1.33-1.44), p<0.0001]. Although associated with diabetes, GlycA had an independent effect on CV events. Moreover, the 
highest tertile of GlycA levels was a stronger predictor of CV events than diabetes. Addition of GlycA to a clinical model improved the 
Akaike information criterion (24138 to 23880) and the likelihood ratio test (LR = 130, p<0.0001). Addition of GlycA to the GRACE Risk 
Score correctly reclassified 96 (8.8%) and 452 (11.3%) patients to higher- and lower-risk categories, respectively, with an overall net 
reclassification improvement of 6% (p<0.0001).
Conclusion:  Consideration of GlycA in addition to traditional risk factors improves CV risk prediction in a high-risk population. The 
performance of GlycA compared to existing inflammatory biomarkers in predicting CV risk, and the effect of therapeutic interventions on 
GlycA levels in relation to CV outcomes, represent important future areas of investigation.
